Human fungal pathogen Candida albicans in the postgenomic era: An overview

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 1, 2009, Pages 121-134

  Kabir, M Anaul ^a   Hussain, Mohammad Asif ^a  

^a P A COLLEGE OF ENGINEERING   (India)

Author keywords

Anti Candida vaccine; Biofilm; Candida albicans; Chromosomal instability; Fungal drug; Pathogen; Unknown open reading frame

Indexed keywords

AMINOCANDIN; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ARYLAMIDINE; CASPOFUNGIN; FLUCONAZOLE; FUNGUS VACCINE; LIPOPEPTIDE; MICAFUNGIN; MONOCLONAL ANTIBODY; NYSTATIN; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN ALS1P; TERBINAFINE; TRIAZOLE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; CHROMOSOME ANALYSIS; DNA SEQUENCE; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FUNGAL GENE; FUNGAL GENETICS; FUNGAL GENOME; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS IDENTIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INTERACTION; GENE SEQUENCE; GENOME ANALYSIS; GENOMIC INSTABILITY; GENOMICS; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; MOLECULAR BIOLOGY; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PROTEOMICS; REVIEW; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; SEQUENCE HOMOLOGY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; GENOME, FUNGAL; HUMANS; OPEN READING FRAMES; SPECIES SPECIFICITY;

EID: 69449105899     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.1.121     Document Type: Review

References (136)

1. Ruhnke M, Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer-review of the literature. Eur. J. Med. Res. 7(5), 227-235 (2002).
2. Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 2(10), 393-400 (1994).
3. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11(2), 382-402 (1998).
4. Odds FC. Candida and Candidiasis (2nd Edition). Bailliere Tindall, London, UK (1988).
5. Calderone RA. Candida and Candidiasis. American Society for Microbiology Press, DC, USA (2002).
6. Dupont B, Drouhet E. Fluconazole for the treatment of fungal diseases in immunosuppressed patients. Ann. NY Acad. Sci. 544, 564-570 (1988).
7. Celebi S, Hacimustafaoglu M, Ozdemir O, Ozkaya G. Nosocomial candidemia in children: results of a 9-year study. Mycoses 51(3), 248-257 (2008).
8. Chakrabarti A, Chatterjee SS, Shivaprakash MR. Overview of opportunistic fungal infections in India. Nippon Ishinkin Gakkai Zasshi 49(3), 165-172 (2008).
9. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 56(2), 126-129 (2008).
10. Shao PL, Huang LM, Hsueh PR. Recent advances and challenges in the treatment of invasive fungal infections. Int. J. Antimicrob. Agents 30(6), 487-495 (2007).
11. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43(9), 4434-4440 (2005).
12. Mishra NN, Prasad T, Sharma N et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Acta Microbiol. Immunol. Hung. 54(4), 201-235 (2007).
13. Tsang CS, Chu FC, Leung WK, Jin LJ, Samaranayake LP, Siu SC. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with Type 2 diabetes mellitus. J. Med. Microbiol. 56(Pt 10), 1393-1398 (2007).
14. Janbon G, Sherman F, Rustchenko E. Monosomy of a specific chromosome determines L-sorbose utilization: a novel regulatory mechanism in Candida albicans. Proc. Natl Acad. Sci. USA 95(9), 5150-5155 (1998).
15. Kabir MA, Ahmad A, Greenberg JR, Wang YK, Rustchenko E. Loss and gain of chromosome 5 controls growth of Candida albicans on sorbose due to dispersed redundant negative regulators. Proc. Natl Acad. Sci. USA 102(34), 12147-12152 (2005).
16. Chen X, Magee BB, Dawson D, Magee PT, Kumamoto CA. Chromosome 1 trisomy compromises the virulence of Candida albicans. Mol. Microbiol. 51(2), 551-565 (2004).
17. Magee BB, Magee PT. Induction of mating in Candida albicans by construction of MTLa and MTLα strains. Science 289(5477), 310-313 (2000).
18. Hull CM, Raisner RM, Johnson AD. Evidence for mating of the "asexual" yeast Candida albicans in a mammalian host. Science 289(5477), 307-310 (2000).
19. Bennett RJ, Johnson AD. Mating in Candida albicans and the search for a sexual cycle. Annu. Rev. Microbiol. 59, 233-255 (2005).
20. Forche A, Alby K, Schaefer D et al. The parasexual cycle in Candida albicans provides an alternative pathway to meiosis for the formation of recombinant strains. PLoS Biol. 6(5), E110 (2008).
21. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol. 9(7), 327-335 (2001).
22. Sudbery P, Gow N, Berman J. The distinct morphogenic states of Candida albicans. Trends Microbiol. 12(7), 317-324 (2004).
23. Jones T, Federspiel NA, Chibana H et al. The diploid genome sequence of Candida albicans. Proc. Natl Acad. Sci. USA 101(19), 7329-7334 (2004).
24. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134(3), 717-728 (1993).
25. van het Hoog M, Rast TJ, Martchenko M et al. Assembly of the Candida albicans genome into sixteen supercontigs aligned on the eight chromosomes. Genome Biol. 8(4), R52 (2007).
26. Rustchenko E, Sherman F. Genetic instability of Candida albicans. In: Fungi Pathogenic for Humans and Animals. Howard DH (Ed.). Marcel Dekker Inc., NY, USA 723-776 (2002).
27. Braun BR, van Het Hoog M, d'Enfert C et al. A human-curated annotation of the Candida albicans genome. PLoS Genet. 1(1), 36-57 (2005).
28. Arnaud MB, Costanzo MC et al. Sequence resources at the Candida Genome Database Nucleic Acid Res. 35, D452-D456 (2007).
29. Nantel A. The long hard road to a completed Candida albicans genome. Fungal Genet. Biol. 43(5), 311-315 (2006).
30. Slutsky B, Staebell M, Anderson J, Risen L Pfaller M, Soil DR. "White - opaque transition": a second high-frequency switching system in Candida albicans. J. Bacteriol. 169(1), 189-197 (1987).
31. Enloe B, Diamond A, Mitchell AP, A single-transformation gene function test in diploid Candida albicans. J. Bacteriol. 182(20), 5730-5736 (2000).
32. Bruno VM, Mitchell AP. Large-scale gene function analysis in Candida albicans. Trends Microbiol. 12(4), 157-161 (2004).
33. Selmecki A, Bergmann S, Berman J. Comparative genome hybridization reveals widespread aneuploidy in Candida albicans laboratory strains. Mol. Microbiol. 55(5), 1553-1565 (2005).
34. Kabir MA, Rustchenko E. Determination of gaps by contig alignment with telomere-mediated chromosomal fragmentation in Candida albicans. Gene 345(2), 279-287 (2005).
35. Kurtz MB, Cortelyou MW, Kirsch DR. Integrative transformation of Candida albicans using a cloned Candida ADE2 gene. Mol. Cell. Biol. 6(1), 142-149 (1986).
36. Ito H, Fukuda Y, Murata K, Kimura A. Transformation of intact yeast cells treated with alkali cations. J. Bacteriol. 153(1), 163-168 (1983).
37. Cannon RD, Jenkinson HF, Shepherd MG. Cloning and expression of Candida albicans ADE2 and proteinase genes on a replicative plasmid in C. albicans and in Saccharomyces cerevisiae. Mol. Gen. Genet. 235(2-3), 453-457 (1992).
38. Köhler GA, White TC, Agabian N. Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid. J. Bacteriol. 179(7), 2331-2338 (1997).
39. Beckerman J, Chibana H, Turner J, Magee PT. Single-copy IMH3 allele is sufficient to confer resistance to mycophenolic acid in Candida albicans and to mediate transformation of clinical Candida species. Infect. Immun. 69(1), 108-114 (2001).
40. Du W, Coaker M, Sobel JD, Akins RA. Shuttle vectors for Candida albicans: control of plasmid copy number and elevated expression of cloned genes. Curr. Genet. 45(6), 390-398 (2004).
41. Lebel K, MacPherson S, Turcotte B. New tools for phenotypic analysis in Candida albicans: the WAR1 gene confers resistance to sorbate. Yeast 23(4), 249-259 (2006).
42. Reuss O, Vik A, Kolter R, Morschhäuser J. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341, 119-127 (2004).
43. Morschhäuser J, Michel S, Staib P. Sequential gene disruption in Candida albicans by FLP-mediated site-specific recombination. Mol. Microbiol. 32(3), 547-556 (1999).
44. Gerami-Nejad M, Berman J, Gale CA. Cassettes for PCR-mediated construction of green, yellow, and cyan fluorescent protein fusions in Candida albicans. Yeast 18(9), 859-864 (2001).
45. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21(Suppl. 1), 33-37 (1999).
46. Johnston M. Feasting, fasting and fermenting. Glucose sensing in yeast and other cells. Trends Genet. 15(1), 29-33 (1999).
47. Vylkova S, Jang WS, Li W, Nayyar N, Edgerton M. Histatin 5 initiates osmotic stress response in Candida albicans via activation of the Hog1p mitogen-activated protein kinase pathway. Eukaryot. Cell 6(10), 1876-1888 (2007).
48. Lan CY, Newport G, Murillo LA et al. Metabolic specialization associated with phenotypic switching in Candida albicans. Proc. Natl Acad. Sci. USA 99(23), 14907-14912 (2002).
49. Nantel A, Dignard D, Bachewich C et al. Transcription profiling of Candida albicans cells undergoing the yeast-to-hyphal transition. Mol. Cell. Biol. 13(10), 3452-3465 (2002).
50. Lan CY, Rodarte G, Murillo LA et al. Regulatory networks affected by iron availability in Candida albicans. Mol. Microbiol. 53(5), 1451-1469 (2004).
51. Bennet RJ, Uhl MA, Miller MG et al. Identification and characterization of a Candida albicans mating pheromone. Mol. Cell. Biol. 23(22), 8189-8201 (2003).
52. De Backer MD, Ilyina T, Ma XJ et al. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob. Agents Chemother. 45(6), 1660-1670 (2001).
53. Rogers PD, Barker KS. Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob. Agents Chemother. 46(11), 3412-3417 (2002).
54. Karababa M, Coste AT, Rognon et al. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob. Agents Chemother. 48(8), 3064-3079 (2004).
55. Liu TT, Lee RE, Barker KS et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 49(6), 2226-2236 (2005).
56. Barker KS, Crisp S, Wiederhold N et al. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J. Antimcrob. Chemother. 54(2), 376-385 (2004).
57. Lorenz MC, Fink GR. The glyoxylate cycle is required for fungal virulence. Nature 412(6842), 83-86 (2001).
58. Menon V, De Bernardis F, Calderone R et al. Transcriptional profiling of the Candida albicans Ssk1p receiver domain point mutants and their virulence. FEMS Yeast Res. 8(5), 756-763 (2008).
59. Bahn YS, Molenda M, Staab JF et al. Genome-wide transcriptional profiling of the cyclic AMP-dependent signaling pathway during morphogenic transitions of Candida albicans. Eukaryot. Cell6(12), 2376-2390 (2007).
60. Griffin TJ, Gypi SP, Ideker I et al. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol. Cell Proteomics 1(4), 323-333 (2002).
61. Rupp S. Proteomics on its way to study host-pathogen interaction in Candida albicans. Curr. Opin. Microbiol. 7(4), 330-335 (2004).
62. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4(12), 3665-3685 (2004).
63. Klose J, Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 16(6), 1034-1095 (1995).
64. Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2(1), 43-50 (2003).
65. Thomas DP, Pitarch A, Monteoliya L, Gil C, Lopez-Ribot JL. Proteomics to study Candida albicans biology and pathogenicity. Infect. Disord. Drug Targets 6(4), 335-341 (2006).
66. Kusch H, Engelmann S, Bode R, Albrecht D, Morschhäuser J, Hecker M. A proteomic view of Candida albicans yeast cell metabolism in exponential and stationary growth phases. Int. J. Med. Microbiol. 298(3-4), 291-318 (2008).
67. Sosinska GJ, de Groot PW, Teixeira de Mattos MJ et al. Hypoxic conditions and iron restriction affect the cell-wall proteome of Candida albicans grown under vagina-simulative conditions. Microbiology 154(Pt 2), 510-520 (2008).
68. Hooshdaran MZ, Hilliard GM, Rogers PD. Application of proteomic analysis to the study of azole antifungal resistance in Candida albicans. Methods Mol. Med. 118, 57-70 (2005).
69. Seneviratne CJ, Wang Y, Jin L, Abiko Y, Samaranayake LP. Candida albicans biofilm formation is associated with increased anti-oxidative capacities. Proteomics 8(14), 2936-2947 (2008).
70. Kusch H, Engelmann S, Albrecht D, Morschhäuser J, Hecker M. Proteomic analysis of the oxidative stress response in Candida albicans. Proteomics 7(5), 686-697 (2007).
71. Morschhäuser J, Staib P, Köhler G. CARE-2 fingerprinting of Candida albicans isolates. Methods Mol. Med. 118, 27-34 (2005).
72. Essendoubi M, Toubas D, Bouzaggou M, Pinon JM, Manfait M, Sockalingum GD. Rapid identification of Candida species by FT-IR microspectroscopy. Biochim. Biophys. Acta 1724(3), 239-247 (2005).
73. Toubas D, Essendoubi M, Adt I, Pinon JM, Manfait M, Sockalingum GD. FTIR spectroscopy in medical mycology: application to the differentiation and typing of Candida. Anal. Bioanal. Chem. 387(5), 1729-1737 (2007).
74. Forrest GN, Mankes K, Jabra-Rizk MA et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J. Clin. Microbiol. 44(9), 3381-3383 (2006).
75. Piao YS, Zhang Y, Yang X, He CY, Liu HG. The use of MUC5B antibody in identifying the fungal type of fungal sinusitis. Hum. Pathol. 39(5), 650-656 (2008).
76. Leinberger DM, Schumacher U, Autenrieth IB, Bachmann TT. Development of a DNA microarray for detection and identification of fungal pathogens involved in invasive mycoses. J. Clin. Microbiol. 43(10), 4943-4953 (2005).
77. Rudensky B, Broide E, Berko N, Wiener-Well Y, Yinnon AM, Raveh D. Direct fluconazole susceptibility testing of positive Candida blood cultures by flow cytometry. Mycoses 51(3), 200-204 (2008).
78. Turner MS, Drew RH, Perfect JR. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs 11(2), 231-250 (2006).
79. Najvar LK, Bocanegra R, Wiederhold NP et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin. Microbiol. Infect. 14(6), 595-600 (2008).
80. Mitsuyama J, Nomura N, Hashimoto K et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob. Agents Chemther. 52(4), 1318-1324 (2008).
81. Saville SP, Lazzell AL, Bryant AP et al. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob. Agents Chemother. 50(10), 3312-3316 2006).
82. Sevilla MJ, Robledo B, Rementeria A, Moragues MD, Ponton J. A fungicidal monoclonal antibody protects against murine invasive candidiasis. Infect. Immun. 74(5), 3042-3045 (2006).
83. Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y, Edwards JE Jr. The anti- Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect. Immun. 74(5), 3039-3041 (2006).
84. Spellberg B, Ibrahim AS, Lin L et al. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J. Infect. Dis. 197(7), 967-971 (2008).
85. Raska M, Belakova J, Wudattu NK et al. Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Folia Microbiol. (Praha) 50 (1), 77-82 (2005).
86. Zeng YB, Qian YS, Ma L. Gu HN. Genome-wide expression profiling of the response to terbinafine in Candida albicans using a cDNA microarray analysis. Chin. Med. J. (Engl.) 120(9), 807-813 (2007).
87. Naglik J, Albrecht A, Bader O, Hube B. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol. 6(10), 915-926 (2004).
88. Fu Y, Rieg G, Fonzi WA, Belanger PH, Edwards JE Jr, Filler SG. Expression of the Candida albicans gene ALS1 in Saccharomyces cerevisiae induces adherence to endothelial and epithelial cells. Infect. Immun. 66(4), 1783-1786 (1998).
89. Staab JF, Bradway SD, Fidel PL, Sundstrom P. Adhesive and mammalian transglutaminase properties of the Candida albicans HWP1. Science 283(5407), 1535-1538 (1999).
90. Gale CA, Bendel CM, McClellan M et al. Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science 279(5355), 1355-1358 (1998).
91. Buurman ET, Westwater C, Hube B, Brown AJP, Odds FC, Gow NAR. Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc. Natl Acad. Sci. USA 95(13), 7670-7675 (1998).
92. Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous Candida albicans mutants are avirulent. Cell 90(5), 939-949 (1997).
93. Liu H. Transcriptional control of dimorphism in Candida albicans. Curr. Opin. Microbiol. 4(6), 728-735 (2001).
94. Berman J. Morphogenesis and cell cycle progression in Candida albicans. Curr. Opin. Microbiol. 9(6), 595-601 (2006).
95. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev. 67(3), 400-428 (2003).
96. Schaller M, Borelli C, Korting HC, Hube B. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 48 (6), 365-377 (2005).
97. Hube B. Infection-associated genes of Candida albicans. Future Microbiol. 1, 209-218 (2006).
98. Mora-Montes HM, Bates S, Netea MG et al. Endoplasmic reticulum α-glycosidases of Candida albicans are required for N glycosylation, cell wall integrity, and normal host-parasite interaction. Eukaryot. Cell 6(12), 2184-2193 (2007).
99. Moran GP, MacCallum DM, Spiering MJ, Coleman DC, Sullivan DJ. Differential regulation of the transcriptional repressor NRG1 accounts for altered host-cell interactions in Candida albicans and Candida dubliensis. Mol. Microbiol. 66(4), 915-929 (2007).
100. Xu Y, Chen L, Li C. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J. Antimicrob. Chemother. 61(4), 798-804 (2008).
101. Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother. 48(6), 2223-2227 (2004).
102. Akins RA. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol. 43(4), 285-318 (2005).
103. Sanglard D, Bille J. Current understanding of the models of action and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. In: Candida and Candidiasis. Calderone RA (Ed.). American Society for Microbiology, DC, USA 349-383 (2002).
104. Baixench MT, Aoun N, Desnos-Ollivier M et al. Acquired resistance to echinocandins in: case report and review. J. Antimicrob. Chemother. 59(6), 1076-1083 (2007).
105. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 11(1), 30-36 (2003).
106. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot. Cell 4(4), 633-638 (2005).
107. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin. Microbiol. Rev. 17(2), 255-267 (2004).
108. Chandra J, Patel JD, Li J et al. Modification of surface properties of biomaterials influences the ability of Candida albicans to form biofilms. Appl. Environ. Microbiol. 71(12), 8795-8801 (2005).
109. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Chemother. 46(3), 397-403 (2000).
110. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183(18), 5385-5394 (2001).
111. Green CB, Cheng G, Chandra J, Mukherjee P, Ghannum MA, Hoyer LL. RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology 150(Pt 2), 267-275 (2004).
112. Zhao X, Daniels KJ, Oh SH et al. Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. Microbiology 152(Pt 8), 2287-2299 (2006).
113. Nobile SG, Andes DR, Nett JE et al. Critical role of Bcr1p-dependent adhesions in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog. 2(7), 636-649 (2006).
114. Nobile CJ, Mitchell AP. Regulation-of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr. Biol. 15(12), 1150-1155 (2005).
115. Kelly MT, MacCallum DM, Clancy SD, Odds FC, Brown AJ, Butler G. The Candida albicans CaACE2 gene affects morphogenesis, adherence and virulence. Mol. Microbiol. 53(3), 969-983 (2004).
116. Mulhern SM, Logue ME, Butler G. Candida albicans transcription factor Ace2p regulates metabolism and is required for filamentation in hypoxic conditions. Eukaryot. Cell 5(12), 2001-2013 (2006).
117. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1p regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett. 214(1), 95-100 (2002).
118. Richard ML, Nobile CJ, Bruno VM, Mitchell AP. Candida albicans biofilm-defective mutants. Eukaryot. Cell 4(8), 1493-1502 (2005).
119. Norice CT, Smith FJ Jr, Solis N, Filler SG, Mitchell AP. Requirement for Candida albicans Sun41p in biofilm formation and virulence. Eukaryot. Cell 6(11), 2046-2055 (2007).
120. Hiller E, Heine S, Brunner H, Rupp S. Candida albicans Sun41p, a putative glycosidase, is involved in morphogenesis, cell wall biogenesis, and biofilm formation. Eukaryot. Cell 6(11), 2056-2065 (2007).
121. Yeater KM, Chandra J, Cheng G et al. Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology 153(Pt 8), 2373-2385 (2007).
122. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71(8), 4333-4340 (2003).
123. Al-Fattani MA, Douglas LJ. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 48(9), 3291-3297 (2004).
124. Mateus C, Crow SA Jr, Ahearn DG. Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob. Agents Chemother. 48(9), 3358-3366 (2004).
125. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49(6), 973-980 (2002a).
126. Kumamoto CA. A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc. Natl Acad. Sci. USA 102(15), 5576-5581 (2005).
127. Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9(6), 588-594 (2006).
128. Rustchenko E. Chromosome instability in Candida albicans. FEMS Yeast Res. 7(1), 2-11 (2007).
129. Larriba G, Calderone RA. Heterozygosity and loss of heterozygosity in Candida albicans. In: Pathogenic Fungi: Insights In Molecular Biology. San-Bias G, Calderone RA (Ed.). Caister Academic Press, Norwich, UK 35-68 (2008).
130. Andaluz E, Gómez-Raja J, Hermosa B et al. Loss and fragmentation of chromosome 5 are major events linked to the adaptation of rad52-DeltaDelta strains of Candida albicans to sorbose. Fungal Genet. Biol. 44(8), 789-798 (2007).
131. Ahmad A, Kabir MA, Kravet A, Andaluz E, Larriba G, Rustchenko E. Genome instability and unusual features of some widely used strains of Candida albicans. Yeast 25(6), 433-448 (2008).
132. Lephart PR, Chibana H, Magee PT. Effect of the major repeat sequence on chromosome loss in Candida albicans. Eukaryot. Cell 4(4), 733-741 (2005).
133. Chibana H, Beckerman JL, Magee PT. Fine-resolution physical mapping of genomic diversity in Candida albicans. Genome Res. 10(12), 1865-1877 (2000).
134. Chu WS, Magee BB, Magee PT. Construction of an SfiI macrorestriction map of the Candida albicans genome. J. Bacteriol. 175(20), 6637-6651 (1993).
135. Pena-Castillo L, Hughes TR. Why are there still over 1000 uncharacterized yeast genes? Genetics 176(1), 7-14 (2007).
136. Oliver S. A network approach to the systematic analysis of yeast gene function. Trends Genet. 12(7), 241-242 (1996).